Page 3 - இணைப்பு திசு புற்றுநோயியல் சமூகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இணைப்பு திசு புற்றுநோயியல் சமூகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இணைப்பு திசு புற்றுநோயியல் சமூகம் Today - Breaking & Trending Today

TodayIR: Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM


(2)
DJ EQS-News: Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM EQS-News / 28/01/2021 / 10:33 UTC+8 Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
Shanghai and Hong Kong, PRC, January 28, 2021 Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and /or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) accepted its New Drug Application (NDA) for ATG-010 (Selinexor, XPOVIO(R)), a first-in-class oral selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma ( rrMM). This is the fifth NDA for ATG-010 submitted by Antengene, after the four NDAs recently submitted in Australia, South Korea, Singapor ....

New Zealand , Hong Kong , South Korea , Kostenloser Wertpapierhandel , Jay Mei , Asia Pacific , Karyopharm Therapeutics Inc , Marketing Press , Drug Administration , Antengene Corporation Limited , European Medicines Agency , National Medical Products Administration , Connective Tissue Oncology Society , National Comprehensive Cancer Network , Antengene Announces , Corporation Limited , New Drug Application , Karyopharm Therapeutics , Marketing Authorization Application , Medicines Agency , Safety Monitoring Board , Asia Pacific Region , Patients Beyond , Marketing Press Release , Dow Jones Newswires , புதியது ஜீலாந்து ,

TodayIR: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy


(2)
DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
EQS-News / 21/12/2020 / 15:21 UTC+8
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has
received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients
with Multiple Myeloma After At Least One Prior Therapy
Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple
Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO(R)
Addressable Patient Population -
Oral XPOVIO(R) is Now the Only Approved Multiple Myeloma Drug Indicated ....

United States , Hong Kong , Jay Mei , Asia Pacific , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , Drug Administration , Australian Therapeutic Goods Administration , Health Sciences Authority , Approval Program , European Medicines Agency , Antengene Corporation Limited , National Medical Products Administration , Connective Tissue Oncology Society , National Comprehensive Cancer Network , Antengene Announces , Combination Therapy , Addressable Patient Population , Only Approved Multiple Myeloma Drug Indicated , Once Weekly Bortezomib Combination Regimen , Multiple Myeloma Drug , New Mechanism , Action Approved , Second Line Setting Since , Comes Approximately Three Months Ahead , New Drug Application ,

Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM


Share this article
Share this article
SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-010 (selinexor), an oral Selective Inhibitor of Nuclear Export compound, in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (rrMM) in China.
The trial is a Phase 3 randomized, controlled, open-label, multicenter clinical trial, aiming to evaluate the efficacy and safety of ATG-010, bortezomib and dexamethasone (SVd) regimen against bortezomib and dexamethasone (Vd) regimen in Chinese adult patients with rrMM who have received one to thr ....

United States , Jay Mei , Asia Pacific , Karyopharm Therapeutics Inc , Antengene Corporation , Drug Administration , Selective Inhibitor Of Nuclear , Prnewswire Antengene Corporation Limited , Antengene Corporation Limited , National Medical Products Administration , Connective Tissue Oncology Society , National Comprehensive Cancer Network , Corporation Limited , Investigational New Drug , Selective Inhibitor , Nuclear Export , Clinical Practice Guidelines , Karyopharm Therapeutics , Safety Monitoring Board , Asia Pacific Region , Patients Beyond , ஒன்றுபட்டது மாநிலங்களில் , ஜெய் மெய் , ஆசியா பெஸிஃபிக் , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு , இணைப்பு திசு புற்றுநோயியல் சமூகம் ,